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There has been considerable interest in determining the optimal way
to combine the taxanes with anthracyclines, as these are the most
active anti-cancer agents available for the treatment of advanced
breast cancer (Hortobagyi and Holmes, 1997). Initial trials of 3-hour
infusions of paclitaxel combined with doxorubicin reported high
response rates, but significant cardiac toxicity (Gianni et al, 1995;
Gehl et al, 1996). Epirubicin has similar efficacy to doxorubicin in
breast cancer, with less cardiac toxicity (Bonadonna et al, 1993).
Hence, combining paclitaxel with epirubicin may be one way of
decreasing the risk of cardiac toxicity while maintaining efficacy.
We have previously reported the results of a single-institution phase
I trial of this combination in minimally pretreated patients, where
the doses were escalated from epirubicin 60 mg m–2 and paclitaxel
155 mg m–2 to 90 mg m–2 and 200 mg m–2 respectively (Rischin et
al, 1999). The dose-limiting toxicities were febrile neutropenia,
oesophagitis and diarrhoea, and the recommended phase II doses
were epirubicin 75 mg m–2 and paclitaxel 175 mg m–2. In the current
trial we have investigated the combination of paclitaxel and epiru-
bicin in advanced breast cancer, using the recommended doses from
our phase I trial.
PATIENTS AND METHODS
Eligibility
Patients were required to have histologically proven advanced
breast cancer. Patients may have received adjuvant chemotherapy
but no prior chemotherapy for advanced disease. Prior anthracy-
cline was permitted if at least 12 months had elapsed between
completion of adjuvant treatment and relapse, and total doxoru-
bicin dose was ≤240 mg m–2. No prior taxane chemotherapy was
permitted. Prior radiotherapy to less than 25% of the marrow-
bearing areas was permitted, but radiotherapy must have been
completed at least 4 weeks prior to study entry. Patients had to
have a bidimensionally measurable lesion with at least one diam-
eter >1 cm. Other eligibility criteria were: age 18–75 years, perfor-
mance status (ECOG) 0–2, absolute neutrophil count ³ 2.0 ´ 109
l–1, platelet count ³ 100 ´ 109 l–1, bilirubin ≤ upper limit of normal,
transaminases ≤2 times upper limit of normal, serum creatinine ≤
1.5 times upper limit of normal and left ventricular ejection frac-
tion (LVEF) measured by radionuclide ventriculography ³ lower
limit of normal. Written informed consent was obtained from all
patients and the protocol was approved by the Institutional Ethics
Committees.
Patients were excluded from the trial for any of the following:
history of atrial or ventricular arrhythmias or cardiac failure,
myocardial infarction within the preceding 6 months, history of
second- or third-degree heart block, brain or bone metastases as
the only known sites of disease, known bone-marrow metastases,
pre-existing peripheral neuropathy > grade 2 by the Common
Toxicity Criteria of the National Cancer Institute, history of other
malignancy except for non-melanoma skin cancer or carcinoma in
situ of the cervix, and pregnancy or lactation.
The phase I and II trials were included in the one protocol, with
additional eligibility criteria for the phase II component including
a diagnosis of advanced breast cancer, bidimensionally measur-
able disease and no prior chemotherapy for advanced disease.
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trial were to be included in the phase II analysis.
Pretreatment and follow-up evaluations
Before enrolment all patients underwent a full history, physical
examination, complete blood count (CBC) with differential, elec-
trolytes, liver function tests, creatinine, ECG, LVEF, and imaging
of known sites of disease. While on study, patients were clinically
assessed for toxicity weekly during the first cycle then every cycle
subsequently. CBC including differential was performed weekly
throughout treatment (twice weekly during first cycle) and elec-
trolytes, creatinine and liver function tests were performed before
each cycle. CT scanning and imaging of known sites of disease
were performed every 2 cycles, as were gated cardiac scans.
Toxicity from treatment was graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC). Anti-tumour
activity was assessed according to the WHO response criteria.
Doses and schedule
All patients received epirubicin 75 mg m–2 followed by paclitaxel
175 mg m–2 as a 3-h infusion, which were the recommended doses
from our phase I trial. Cycles were repeated every 3 weeks. Dose
escalation was not permitted in individual patients and the
minimum interval between treatment cycles was 21 days. As the
potential incidence of cardiac toxicity could not be accurately
determined from phase I trials, it was decided to limit the number
of cycles to a maximum of six. Patients with progressive disease
were taken off study.
Drug administration
Paclitaxel (Anzatax™) was supplied by Faulding Hospital
Pharmaceuticals (Melbourne, Australia) as a sterile solution in
polyethoxylated castor oil (Cremophor EL) and ethanol (50:50
v/v). Epirubicin (Pharmorubicin) was obtained from Pharmacia-
Upjohn (Sydney, Australia). Epirubicin was administered first
over 15–20 min followed immediately by a 3-h infusion of pacli-
taxel. Paclitaxel was diluted in 500 ml dextrose 5% and stored in a
sterile glass container and administered through polyethylene-
lined tubing with a cellulose acetate 0.22-mm in-line filter. Prior to
every cycle patients were premedicated with dexamethasone 20
mg orally, 12 and 6 h before the paclitaxel infusion, and cimetidine
300 mg (alternatively ranitidine 50 mg) and promethazine 25 mg
both intravenously, 30 min prior to the paclitaxel infusion.
Prophylactic recombinant granulocyte colony stimulating factor
(G-CSF) support was not permitted.
Dose modifications for toxicity
Dose reductions were defined for haematologic and non-haemato-
logic toxicities. Epirubicin and paclitaxel doses were to be reduced
by 25% for febrile neutropenia, nadir neutrophil count <0.5 ´ 109
l–1 for ³7 days, or nadir platelet count <50´109 l–1. No dose modifi-
cation was made for uncomplicated neutrophil count <0.5´109 l–1
for <7 days. If the day 21 neutrophil count was <1.5 ´ 109 l–1, or
the platelet count <100 ´ 109 l–1, further treatment was delayed
weekly until recovery. WHO grade 3 or 4 non-haematologic toxi-
city were generally managed by a 25% dose reduction of both
drugs. However, patients could be managed by symptomatic treat-
ment alone or removal from the study at the investigator’s discre-
tion. Clinically significant hypersensitivity reactions (defined as
hypotension that required therapy, angioedema, respiratory
distress requiring bronchodilator therapy, or generalized urticaria)
required cessation of the paclitaxel infusion and appropriate
supportive measures.
Statistics
The primary outcome measure was response rate, with secondary
outcomes including progression-free and overall survival and toxi-
city. 95% confidence intervals for the response rates were esti-
mated using the exact probabilities of the binomial distribution
(StatXact, 1999). The close-out date for survival analyses was
October 1, 1998. The median potential follow-up time from
commencing treatment to the close-out date was 22 months, range
11.5–43 months. Overall survival and progression-free survival
from the commencement of protocol treatment were estimated
using the Kaplan–Meier product-limit method. For overall
survival, all deaths were counted regardless of cause and survival
times for living patients were censored at the close-out date. For
progression-free survival, progression at any site or death from
any cause was counted as an event, with censoring at the 
close-out date for patients surviving without progression. The
Brookmeyer–Crowley method was used to estimate 95% confi-
dence intervals for median survival times (S-plus, 1997).
RESULTS
Patient characteristics
Forty-five patients from six Australian centres were enrolled in
this trial between March 1995 and October 1997. Two patients
were subsequently found to be ineligible due to prior
chemotherapy for metastatic disease. The details of the remaining
43 patients enrolled on this study are given in Table 1. Five of
these patients were treated on the phase I study (Rischin et al,
1999), and also included in this analysis as originally intended, as
they were treated at the recommended dose level and fulfilled all
the eligibility requirements for the phase II trial.
Treatment
Two hundred and sixteen cycles of treatment (median 6, range
2–6) were given. Sixty-seven percent of patients received all six
cycles. Reasons for ceasing treatment prior to six cycles were:
progressive disease 21%, toxicity 7%, death 2% and patient
request 2%. The toxicities that resulted in treatment cessation
were: fatigue, reduced left ventricular ejection fraction and
treating physician decision to withdraw a patient with a urinary
tract infection and neutropenia. The death was the result of a non-
neutropenic chest infection 3 days after receiving the fifth cycle.
Eighteen (42%) patients required 22 dose reductions, predomi-
nantly for low blood counts and febrile neutropenia.
Toxicity
Worst toxicities experienced during treatment are given in Table 2.
Neutropenia was the predominant toxicity, with 95% of patients
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febrile neutropenia only occurred in six (14%) patients, and eight
(4%) cycles. Grade 4 neutropenia lasting ³7 days occurred in four
patients, one cycle each. Grade 3 or 4 non-haematologic toxicity
was uncommon. Four patients required dose delays due to slow
recovery from myelosuppression, with one patient requiring a
dose delay on two occasions.
The median cumulative dose of epirubicin was 371 mg m–2
(range 131–459). Four patients had a decrease in the left ventric-
ular ejection fraction (LVEF) of ³20% of baseline value, and in
two patients the LVEF decreased to below the lower limit of
normal, but no patient developed clinical evidence of cardiac
failure. None of these four patients had received prior anthracy-
clines. In the three patients who had previously received doxoru-
bicin the LVEF remained within the normal range and the decrease
in LVEF was <20%. In 20 patients who received ³400 mg m–2
epirubicin the mean change in LVEF, expressed as a percentage of
the baseline value, was a decrease of 11%.
Responses
Five patients (12%) achieved a complete response and 18 (42%) a
partial response to give an overall response rate of 54% (95% CI
38–69%). Thirteen patients (30%) had stable disease and seven
(16%) had progressive disease. Of the five complete responders,
two had visceral disease, two nodal involvement and one had
chest-wall disease. The response rate in patients who had received
adjuvant chemotherapy was not significantly different from that in
patients who had received no prior chemotherapy, 53% and 54%
respectively. One of the three patients who had received prior
anthracycline achieved a partial response.
Survival
By the close-out date 34 patients (79%) had progressed or relapsed
and 22 (51%) had died of their disease. One additional patient
(2%) died without progression due to a chest infection.
Progression-free survival is demonstrated in Figure 1. The esti-
mated median progression-free survival is 6.9 months (95% CI
5.4–10.0). Overall survival is demonstrated in Figure 2. The esti-
mated median survival is 17.9 months (95% CI 14.2–25.7). No
second-line treatment was specified in the protocol. Of the 34
patients who progressed, seven were given no further systemic
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Table 1 Patient characteristics (n = 43)
Median age (range) 52 years (35–70)
Performance status (ECOG)
01 8
12 1
24
Adjuvant chemotherapy
None 24
CMF(P) 16
Anthracycline + CMF 3
Prior hormonal therapy 28
Prior radiotherapy 25
Disease sites
Visceral +/– bone +/– soft tissue 31
Bone +/– soft tissue 6
Soft tissue only 6
Table 2 Toxicity
Worst gradea (percentage of patients)
012 3 4
Haemoglobin 12 42 40 7 0
Neutrophils 0 0 2 2 95
Platelets 47 42 5 5 2
Stomatitis 56 14 26 5 0
Nausea 33 42 19 7 –
Vomiting 56 19 23 2 0
Diarrhoea 77 14 5 2 2
Sensory neuropathy 42 44 14 0 –
Motor neuropathy 98 2 0 0 0
Cardiac function 93 2 5 0 0
Alopecia 2 2 95 – –
Infection 70 0 12 19 –
Myalgia/arthralgia 28 33 26 14 –
Asthenia 37 30 21 12 –
aFor non-haematological toxicities, worst grade considered to be related to
study drugs
Months following commencement of treatment
E
s
t
i
m
a
t
e
d
 
%
 
s
u
r
v
i
v
i
n
g
 
w
i
h
o
u
t
 
p
r
o
g
r
e
s
s
i
o
n
Number at risk
0
0
20
40
60
80
100
6 12 18 24 30
43 25 10 4 3 2
36
0
Figure 1 Progression-free survival of all patients. Vertical marks indicate
censoring for patients surviving progression-free at the close-out date
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Figure 2 Overall survival of all patients. Vertical marks indicate censoring
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treatment prior to the close-out date, four received radiotherapy
alone, four received hormonal therapy and 19 received second-line
chemotherapy. This consisted of cyclophosphamide, methotrexate
and 5-Fluorouracil in 13 cases and various regimens in the other
six. Data was not collected about responses to these treatments.
DISCUSSION
This multi-centre phase II trial has demonstrated that the combina-
tion of paclitaxel and epirubicin is a promising regimen, achieving
an objective response rate of 54% and median survival of 17.9
months, with an acceptable toxicity profile. Previous trials with
paclitaxel and doxorubicin have reported response rates of
47–94% (Gianni et al, 1995; Hortobagyi and Holmes, 1997;
Sledge et al, 1998). Conte et al (1997) have reported a response
rate of 84% with paclitaxel and epirubicin, but other trials have
reported response rates of 43–68% (Carmichael et al, 1997;
Catimel et al, 1997; Luck et al, 1997). Differences in patient popu-
lations treated may partly account for differences in activity
observed. Furthermore, there were differences in trial design
between the trial reported by Conte et al (1997) and our trial.. In
particular, Conte used higher doses of paclitaxel and epirubicin,
gave prophylactic ciprofloxacin and fluconazole to all patients and
permitted the use of G-CSF at all dose levels to shorten the dura-
tion of grade 4 neutropenia or in the event of febrile neutropenia.
The use of higher doses of epirubicin and paclitaxel with G-CSF
resulted in a higher dose intensity than was achieved in our trial,
and this may have contributed to the difference in response rates
between the two trials. However, we have previously reported that
the addition of G-CSF did not permit any further dose escalation in
our phase I trial of paclitaxel and epirubicin (Rischin et al, 1999),
hence our decision not to use G-CSF in the phase II trial. The role
of G-CSF in patients with advanced breast cancer receiving
conventional dose chemotherapy remains unproven.
In view of the promising phase II results achieved with anthra-
cycline and taxane combinations in advanced breast cancer,
several phase III trials are addressing the role of such combina-
tions in breast cancer in both the adjuvant and advanced disease
settings (Conte and Gennari, 1997). Sledge et al (1997) reported a
higher response rate and longer time to treatment failure with
paclitaxel (24-h infusion) and doxorubicin compared to single-
agent paclitaxel or single-agent doxorubicin, but there was no
significant difference in overall survival (Sledge et al, 1998). It
remains unclear whether such combinations are superior to the
sequential use of taxanes and anthracyclines, but ongoing trials
should assist in resolving this question. Paclitaxel and anthracy-
cline combinations have not been compared directly to docetaxel
and anthracycline combinations in randomized trials. In a prelimi-
nary report the combination of docetaxel and doxorubicin resulted
in a superior response rate compared to the combination of
doxorubicin and cyclophosphamide (Nabholtz et al, 1999).
No cases of congestive cardiac failure were observed in our
phase I trial, the current phase II trial, or in the trial of Conte et al
(1997). However, patients received a maximum of six cycles on
this trial, and hence the median cumulative dose of epirubicin was
relatively low at 371 mg m–2. Cardiotoxicity was a major compli-
cation in initial trials combining 3-h infusions of paclitaxel with
doxorubicin, with a 20% incidence of congestive cardiac failure
reported (Gianni et al, 1995; Gehl et al, 1996). Pharmacokinetic
studies have demonstrated increased plasma concentrations of
doxorubicin and/or doxorubicinol when doxorubicin is given with
paclitaxel (Holmes et al, 1996; Gianni et al, 1997a; Berg et al,
1994), and this may contribute to the increased risk of cardiac toxi-
city. Paclitaxel is formulated in 50% Cremophor EL (cremophor),
which can result in similar alterations to doxorubicin pharmacoki-
netics when administered without paclitaxel (Millward et al,
1998). Epirubicin has similar efficacy with less cardiotoxicity than
doxorubicin, and the pharmacokinetic interaction with paclitaxel
may be less clinically significant than with doxorubicin (Conte
and Gennari, 1997; Gianni et al, 1997b; Rischin et al, 1999). The
lower risk of cardiac toxicity may be a potential advantage for
combination chemotherapy with paclitaxel, and has provided the
impetus for current phase III trials which are investigating the role
of paclitaxel and epirubicin in the treatment of both early and
advanced breast cancer.
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